The Safety and Efficacy of Interleukin-17 Inhibitors for Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis

Abstract

Keywords

hidradenitis suppurativa interleukin-17 biologic secukinumab bimekizumab brodalumab ixekizumab

Get full access to this article

View all access options for this article.

References

Jemec

. Hidradenitis suppurativa. N Engl J Med. 2012;366(2):158-164. doi:10.1056/NEJMcp1014163

Liu

Ying

, et al The IL-23/IL-17 pathway in inflammatory skin diseases: from bench to bedside. Front Immunol. 2020;11:594735. doi:10.3389/fimmu.2020.594735

Higgins

Savović

Page

Elbers

Sterne

. Assessing risk of bias in a randomized trial. In: Cochrane Handbook for Systematic Reviews of Interventions. 2019:205-228.

Frew

Navrazhina

Grand

, et al The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: an open-label cohort study. J Am Acad Dermatol. 2020;83(5):1341-1348. doi:10.1016/j.jaad.2020.05.007

Kearney

Hughes

Kirby

. Treatment of hidradenitis suppurativa with brodalumab in biologic treatment failures: experiences from a specialty clinic. Clin Exp Dermatol. 2023;48(7):790-792. doi:10.1093/ced/llad130

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.02 MB

0.01 MB

0.03 MB

0.06 MB

0.08 MB

0.05 MB